Background: microcirculation disorders play a significant role in development of post-COVID syndrome caused by SARS-CoV-2. However, there are no studies on microcirculation parameters during pharmacotherapy in patients with post-COVID syndrome. Materials and methods: analysis of the clinical case of post-COVID syndrome  in the patient who was followed up in the Center of Therapeutic Ophthalmology between February and September 2021. Bulbar conjunctival angioscopy (BCA) was performed to compare the morphofunctional indicators of microcirculation  before and after the treatment. Results: clinical observation of a 23 year-old female with post-COVID syndrome mainly represented by neuropsychiatric manifestations and microcirculation dysfunction as determined with BCA . The patient received pharmacotherapy with meldonium, ethylmethylhydroxyperidine succinate and meglumine sodium succinate Conclusions: prescribed pharmacotherapy led to significant improvement in patient’s condition with simultaneous improvement in morphofunctional parameters assessed with BCA. It indicates improvement of microcirculation processes and supports their role in post-COVID syndrome development. Also the obtained data suggest that BCA can be used for assessment of the post-COVID syndrome’s severity as well as of treatment’s efficacy and safety.

Yulia Danilogorskaya has completed her PHD from Sechenov University, Russian Federation. She is a cardiologist and the deputy head of Center of Therapeutic Ophthalmology, Moscow, Russian Federation. She has over 25 publications on chronic heart failure, atherosclerosis, microcirculation disorders in patients with diabetes mellitus, arterial hypertension, ischemic heart disease.